Pilot Testing Phase Ends; Expansion Of Sales Force Begins

Share Article

PreEmptive Meds, Inc., a plant-based pharma-nutraceutical company, which promotes its proprietary, all-natural formulations as evidence-based alternatives for the primary care physician, announces the completion of its pilot testing phase and its initiation of sales force expansion.

PreEmptive Meds, Inc.

From our pilot program we learned how to promote our products effectively to Primary Care Physicians, and in every sales territory we now expand to we have doctors eager to hear our message and adopt our products as alternatives for their patients.

PreEmptive Meds, Inc., a plant-based pharma-nutraceutical company, which promotes its proprietary, all-natural formulations as evidence-based alternatives for the primary care physician, announces the completion of its pilot testing phase and its initiation of sales force expansion.

Over the past three years, the company has been promoting, on a pilot test basis, its current product line with experienced pharmaceutical-trained sales associates to physicians in selected pockets of northern New Jersey, New York City and Long Island, NY with favorable acceptance and patient outcomes. The Company has now expanded its sales effort to 16 sales associates and plans to continue its expansion to 30 sales associates by July 1st, 2010. The current sales effort is and will be focused up and down the east coast corridor from Massachusetts to Florida, and into Texas, Pennsylvania and Illinois. Expansion is planned to continue throughout 2011 with the goal to have a national sales effort within prominent high-density metropolitan Primary Care Physician areas across the country.

The Company currently promotes seven products: PreCrea® for pre-diabetes; PreLipid® and PreLipid Plus®, for lowering cholesterol naturally; PreMenora® and PreMenora®Plus, for relieving symptoms of perimenopause; and PreArthros™, and PreArthros™Plus for joint inflammation and pain, via a pharmaceutical style sales force. In addition, the Company has also developed a series of new formulations as viable all-natural alternatives for various chronic conditions, which it plans to launch over time once it has established a sufficient beachhead with its current product line with Primary Care Physicians.

Chuck Blitzer, the Company’s Chief Executive Officer stated, “We are extremely pleased with the results from our pilot testing program (which reached over 1,500 physicians and over 200,000 patient experiences) and now, our effort to formally begin building a national sales organization. Our sales associates are highly proven individuals from the pharmaceutical industry and average over 12 years of direct selling experience within the Primary Care Physician community, the largest physician audience in the country.

Our products are recommended by thousands of physicians as:

1) First-line therapy for pre-disease states, where no prescription drugs are approved,
2) An alternative for patients who are intolerant to prescription drugs or refuse to go onto a prescription drug, and
3) Additive therapy to a given prescription drug where the desired therapeutic effect of such drug has not been achieved and the physician is inclined not to increase dose.”

The Company’s financial position is sound and it hasn’t needed to raise capital since its last round of financing in 2008. It is debt free and believes it is on track to break-even by years’ end.

Dr. Joe Fenn, President and Chief Medical Officer stated “From our pilot program we learned how to promote our products effectively to Primary Care Physicians, and in every sales territory we now expand to we have doctors eager to hear our message and adopt our products as alternatives for their patients. We have also established the efficacy and safety of our products in tens of thousands of patients. ”

PreEmptive Meds, Inc., is a pre-disease focused, plant-based pharma-nutraceutical company promoting its proprietary branded products directly to the Primary Care Physician community.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joe Fenn

Chuck Blitzer
Visit website